The Systems Biology of Drug Resistance in Cancer group, led by professor Sampsa Hautaniemi, focuses on understanding and finding effective means to overcome drug resistance in cancers. Our approach is to use systems biology, i.e., analyze molecular & clinical data from cancer patients with machine learning and mathematical methods, to identify efficient patient-specific therapeutic targets. Our work is cross-disciplinary and done in close collaboration with researchers from various disciplines, including clinicians, cell biologists and geneticians. The main objective of our research is to obtain hypotheses and predictions that can be tested in wet-lab or in clinical trials and thereby translate medical data into benefits in cancer patient care.
Read more
@HautaniemiLab

.@Sampsa_H and @KaisaHuhtinen presenting results of the @SuomenAkatemia funded OVCURE project on personalized combi… twitter.com/i/web/status/1…

GDPR uhkaa kansainvälisiä syövän tutkimushankkeita. ”Syöpärekisterin arvokkaan tietopohjan käyttö tieteellisessä tu… twitter.com/i/web/status/1…

So grateful for the @Syopasaatio large grant to support our #OvarianCancer #drugresistance research / Suuret kiitok… twitter.com/i/web/status/1…

Genomic profiling of the residual disease of advanced high‐grade serous ovarian cancer after neoadjuvant chemothera… twitter.com/i/web/status/1…